Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43
Benzinga Newsdesk 58 minutes ago
Analyst RatingsNewsPrice Target
Stifel analyst Stephen Willey maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $43.
Stifel analyst Stephen Willey maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $43.